MIAMI BEACH, Fla., May 22, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) today announced that PennantPark Senior Secured Loan Fund I LLC (“PSSL”) through PSSL’s wholly-owned and consolidated subsidiary, PennantPark CLO VI, LLC (“CLO VI”) has closed the reset of a four-year reinvestment period, twelve-year final maturity $315.8 million debt securitization. The debt issued in this securitization (the “Debt”) is structured in the following manner: ClassPar Amount( ...

Core Insights - The Joint Corp. has elected Christopher M. Grandpre to its board of directors to support long-term growth objectives including new clinic openings, system-wide sales, comparable sales, and Adjusted EBITDA [1][2] Company Overview - The Joint Corp. is the largest provider of chiropractic care in the U.S. through The Joint Chiropractic network, focusing on making chiropractic care accessible and affordable without the need for insurance [5] - The company operates over 950 locations nationwide and has more than 14 million patient visits annually, positioning itself as a leader in the chiropractic industry [5] Leadership and Expertise - Christopher M. Grandpre brings over 30 years of experience in multi-branded franchise companies and M&A investment banking, having served as chairman of Empower Brands, which has sales exceeding $1.5 billion [3][4] - Grandpre's background includes founding Outdoor Living Brands and holding executive roles at various financial institutions, providing a unique perspective to The Joint's leadership [3][4] Business Model and Strategy - The Joint Corp. revolutionized chiropractic care access with its retail healthcare business model introduced in 2010, focusing on convenience and affordability for patients [5] - The company is recognized in various industry rankings, including Franchise Times' "Top 400" and Entrepreneur's "Franchise 500," highlighting its growth and innovation in the franchise sector [5]

Group 1 - Vornado Realty Trust's 55% owned joint venture has agreed to sell a Class A office building at 512 West 22nd Street for $205 million, with the sale expected to close in Q3 2025 [1] - The joint venture plans to use part of the proceeds to repay a $123.6 million mortgage loan on the property [1] - In January 2025, Vornado's 52% owned street retail joint venture completed the sale of a portion of its flagship store at 666 Fifth Avenue to UNIQLO for $350 million, realizing net proceeds of $342 million [2] Group 2 - Vornado focuses on high-rent, high-barrier-to-entry geographic markets and has a diversified tenant base, which is expected to support long-term growth [3] - Over the past month, Vornado's shares have increased by 14.5%, outperforming the industry average increase of 1.3% [3] Group 3 - Other better-ranked stocks in the REIT sector include VICI Properties and Cousins Properties, both rated Zacks Rank 2 (Buy) [4] - The Zacks Consensus Estimate for VICI's 2025 FFO per share has been revised upward to $2.34, while CUZ's estimate has increased by 1.1% to $2.79 [4]

Paving the way for a new industrial future The new facility is a joint venture between PIF and Hyundai Motor Company The plant will manufacture internal combustion engine and electric vehicles, with an annual production target of 50,000 vehicles to supply Saudi Arabia KING ABDULLAH ECONOMIC CITY, Saudi Arabia, May 14, 2025 /PRNewswire/ -- Hyundai Motor Manufacturing Middle East (HMMME), a joint venture between PIF and Hyundai Motor Company, today hosted its groundbreaking ceremony in the recently announced ...

The Joint Corp. (JYNT) shares have declined 4.2% since the company reported first-quarter 2025 results on May 8. Its weaker-than-expected earnings were caused by increased expenses under different heads, partially offset by higher system-wide sales.JYNT reported an adjusted loss of 3 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 2 cents. However, the bottom line remained stable year over year.Revenues increased 7% year over year to $13.1 million. The top line surpassed the ...

Five Point Holdings, LLC (NYSE: FPH ) is a deep value play poised for a re-rating as the market misjudges the long-term monetization potential of its California land bank and underestimates the gains from itsAn economics graduate with a passion for financial history; I apply my knowledge to markets in an effort to hopelessly predict trends and spot value. All opinions are my own and should not be taken seriously.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the co ...

Core Viewpoint - ThreeD Capital Inc. has entered into a Joint Operating Agreement with its CEO Sheldon Inwentash to monetize complementary digital assets, specifically HyperCycle tokens and masternodes, aiming to generate income through the HyperCycle decentralized AI computation ecosystem [1][2]. Group 1: Agreement Details - The Joint Operating Agreement involves ThreeD contributing 6,291,456 HyperCycle tokens valued at approximately $550,000 USD, while Mr. Inwentash contributes 12 HyperCycle masternodes of equal value [2]. - Each party retains beneficial ownership of their contributed assets, with ThreeD maintaining control of the HyperCycle tokens and Mr. Inwentash retaining ownership of the masternodes, which will be temporarily managed by ThreeD for operational purposes [3]. - Revenues and expenses from the Joint Operation will be shared equally (50/50) between ThreeD and Mr. Inwentash, with an income cap of $2,000,000 CAD, at which point the operation will terminate and assets will be returned [4]. Group 2: Regulatory and Compliance Aspects - The transaction is classified as a related party transaction under Multilateral Instrument 61-101, with exemptions from formal valuation and minority approval requirements due to the transaction's value being below 25% of the Company's market capitalization [5]. - The transaction is subject to approval from the Canadian Securities Exchange [6]. Group 3: Company Overview - ThreeD Capital Inc. is a publicly-traded Canadian venture capital firm focused on opportunistic investments in junior resources and disruptive technologies, aiming to invest in early-stage companies globally [7].

The Joint Corp. (JYNT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.06, delivering no surprise.Over the last four quarters, the company has not been ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _________________ Commission file number: 001-36724 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware (State or other j ...

Financial Data and Key Metrics Changes - System wide sales for Q1 2025 were $132.6 million, up 5% compared to Q1 2024, indicating resilience in the current economic environment [10] - Revenue from continuing operations increased by 7% to $13.1 million compared to $12.2 million in Q1 2024 [29] - Adjusted EBITDA from continuing operations was $46,000, a significant decrease from $425,000 in Q1 2024 [10][29] - Net loss from continuing operations was $506,000, compared to a loss of $399,000 in Q1 2024 [30] Business Line Data and Key Metrics Changes - Comp sales for all clinics open for at least 13 months were up 3% for Q1 2025 and increased to 4% in March 2025 [10][24] - Comp sales for mature clinics (open for at least 48 months) were down 2% [24][82] - The company refranchised two corporate clinics and opened five franchise clinics during Q1 2025, with a total of 969 clinics, of which 847 (87%) are franchise clinics [25][26] Market Data and Key Metrics Changes - The company expects system wide sales for 2025 to be between $550 million and $570 million, compared to $530.3 million in 2024 [32] - Comp sales for clinics open for 13 months or more are expected to be in the mid-single digits for 2025 [32] Company Strategy and Development Direction - The company aims to become a pure play franchisor, with 93% of corporate clinics under Letters of Intent (LOIs) for refranchising [12][51] - The strategy includes dynamic revenue management, strengthening digital marketing, and enhancing patient-facing technology [12][19][22] - The company is focusing on pain-centric messaging to attract new patients, as 74% of new patients cite pain as a reason for visiting [35][39] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic consumer environment and is closely monitoring the situation while pushing ahead with the transition plan [11] - The company anticipates a transformative financial impact as clinics shift from company-owned to franchise clinics, leading to increased franchise royalties and fees [34] - Economic headwinds, inflation, and volatile consumer sentiment are expected to impact the beginning of 2025, but the company remains optimistic about future profitability [34] Other Important Information - The company has welcomed new executives to enhance legal strategy and operations, aiming to improve clinic quality and economics [41] - The Joint has been recognized as one of the fastest-growing franchises and ranked in the Franchise 500 [41] Q&A Session Summary Question: New patient ad metrics and retention trends - Management noted that new patient volumes have been affected by overall consumer sentiment, but retention rates remain stable [44][46] Question: Metrics on profitability and overhead reduction - Management is not ready to provide specific metrics but expects profitability to improve as G&A expenses are reduced [47][49] Question: Timeline for refranchising process completion - Management intends to exit 2025 as a pure play franchisor and hopes to accelerate the refranchising process [51] Question: Comp sales performance and dynamics - Management did not disclose April comp sales but confirmed a return to 4% in March [57] - Franchise clinic comp performance mirrors consolidated comp, with corporate clinic comp trailing slightly [59] Question: Dynamic pricing opportunities - Management is exploring various pricing models, with potential for double-digit impacts on system wide sales [61] Question: Selling and marketing expenses normalization - Management expects selling and marketing expenses to normalize by Q3 2025 after a dual agency transition [68] Question: Strategies for mature clinics to improve comp sales - Management is implementing operational strategies and marketing tactics aimed at strengthening existing clinics [83][85]